Segment Information (Tables)

9 Months Ended

Mar. 31, 2023

Disaggregation of Revenue [Table Text Block]


	Three Months Ended March 31,
(in millions)	2023		2022
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	46,497	$	40,723
Nuclear and Precision Health Solutions (3)	312		234
Pharmaceutical segment revenue	46,809		40,957
Medical distribution and products (4)	3,034		3,283
Cardinal Health at-Home Solutions	650		601
Medical segment revenue	3,684		3,884
Total segment revenue	50,493		44,841
Corporate (5)	(6)		(5)
Total revenue	$	50,487	$	44,836


	Nine Months Ended March 31,
(in millions)	2023		2022
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	139,435	$	121,501
Nuclear and Precision Health Solutions (3)	875		653
Pharmaceutical segment revenue	140,310		122,154
Medical distribution and products (4)	9,273		10,296
Cardinal Health at-Home Solutions	1,986		1,822
Medical segment revenue	11,259		12,118
Total segment revenue	151,569		134,272
Corporate (5)	(10)		(11)
Total revenue	$	151,559	$	134,261

(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."

(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3)Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.

(4)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.

(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue from External Customers by Geographic Areas [Table Text Block]

The following tables present revenue by geographic area:


	Three Months Ended March 31,
(in millions)	2023		2022
United States	$	49,326	$	43,710
International	1,167		1,131
Total segment revenue	50,493		44,841
Corporate (1)	(6)		(5)
Total revenue	$	50,487	$	44,836


	Nine Months Ended March 31,
(in millions)	2023		2022
United States	$	148,136	$	130,933
International	3,433		3,339
Total segment revenue	151,569		134,272
Corporate (1)	(10)		(11)
Total revenue	$	151,559	$	134,261

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment

The following tables present segment profit by reportable segment and Corporate:


	Three Months Ended March 31,
(in millions)	2023		2022
Pharmaceutical (1)	$	600	$	487
Medical	20		59
Total segment profit	620		546
Corporate	(48)		(643)
Total operating earnings/(loss)	$	572	$	(97)


	Nine Months Ended March 31,
(in millions)	2023		2022
Pharmaceutical (1)	$	1,495	$	1,319
Medical	29		232
Total segment profit	1,524		1,551
Corporate	(934)		(2,183)
Total operating earnings/(loss)	$	590	$	(632)

(1)Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18 million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.

Assets by Reportable Segment

The following table presents total assets for each reportable segment and Corporate at:


(in millions)	March 31, 2023		June 30, 2022
Pharmaceutical	$	27,954	$	26,409
Medical (1)	10,544		11,632
Corporate	4,879		5,837
Total assets	$	43,377	$	43,878

(1)Medical reflects cumulative $863 million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.